Individualized therapy - The modern standard in wet AMD care

Article

Novartis sponsored a symposium at the COPHy congress in 2012 exploring the current treatment issues surrounding wet AMD. This supplement reveals the highlights of the meeting.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
Related Content
A pharmacy in Montreal, Quebec, its "pharmacie" sign in French. Concept image for RAMQ approval of Vabysmo faricimab injection roche for macular oedema secondary to retinal vein occlusion. Image credit: ©Andriy Blokhin – stock.adobe.com

Québec announces faricimab (Vabysmo, Roche) will be funded for macular oedema secondary to RVO

Martin David Harp
August 23rd 2025
Article
PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

August 23rd 2025
Podcast
A baby is hugged by their parent in a doctor's office during an exam. Concept image for retinoblastoma diagnosis and treatment, importance of early intervention in paediatric ocular disease. Image credit: ©phoderstock – stock.adobe.com

Patient outcomes in retinoblastoma impacted by parents' interventional delays

Lynda Charters
August 23rd 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

August 23rd 2025
Podcast
Tyson J. Brunstetter, MBA, OD, PhD, FAAO, FAsMA presents a keynote on spaceflight-associated neuro-ocular syndrome (SANS). (All images courtesy of Heidelberg Engineering)

Recap: The future of imaging is out of this world

Hattie Hayes
August 23rd 2025
Article
A glass building with a sign reading "RESERVE BANK." There are $100 Australian bank notes superimposed over the image. Concept image for Mirugen funding, cell reprogramming biologic biotech business of retina care news. Image credit: ©Rose Makin – stock.adobe.com

Australian biotech firm Mirugen secures major funding for cell reprogramming therapy

Hattie Hayes
August 23rd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.